Stock SMTI SANARA MEDTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Sanara MedTech Inc.

Equities

SMTI

US79957L1008

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-01 EDT 		5-day change 1st Jan Change
31.23 USD -1.92% Intraday chart for Sanara MedTech Inc. -3.91% -24.01%
04-18 Sanara Medtech Inc. Announces $55 Million Debt Facility CI
04-05 Sanara MedTech Appoints Jake Waldrop as Chief Operating Officer MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call Dates
AQ
Sanara MedTech Inc. Announces $55 Million Debt Facility
AQ
Sanara Medtech Inc. Announces $55 Million Debt Facility
CI
Sanara MedTech Appoints Jake Waldrop as Chief Operating Officer
MT
Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer
AQ
Sanara MedTech Inc. Announces Executive Changes, Effective April 15, 2024
CI
Cantor Fitzgerald Cuts Price Target on Sanara MedTech to $44 From $49, Maintains Overweight Rating
MT
Transcript : Sanara MedTech Inc., Q4 2023 Earnings Call, Mar 26, 2024
Earnings Flash (SMTI) SANARA MEDTECH Posts Q4 Revenue $17.7M, vs. Street Est of $16.5M
MT
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results
AQ
Sanara MedTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates
AQ
Sanara MedTech Reports Higher Preliminary Q4 Revenue
MT
Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023
AQ
Sanara MedTech Inc. Announces Unaudited Preliminary Net Revenue Results for the Fourth Quarter and Full-Year 2023
CI
Sanara MedTech Inc. Announces Exclusive License Agreement for Patented Collagen Peptides
AQ
Sanara MedTech Secures Exclusive Licensing Deal with Tufts University for 18 Collagen Peptides
MT
Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing
AQ
Cantor Fitzgerald Adjusts Price Target on Sanara MedTech to $49 From $59, Maintains Overweight Rating
MT
Transcript : Sanara MedTech Inc., Q3 2023 Earnings Call, Nov 14, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SMTI Stock
  4. News Sanara MedTech Inc.